Rituximab treatment for patients with NMOSD

Abstract

Rituximab was approved on 20^th June, 2022 based on the results of the RIN–1 study : a multicentre, randomised, double–blind, placebo–controlled trial for evaluating the safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (NMOSD). We discussed the current states and issues of rituximab use in patients with NMOSD.